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hospitalisation;
pyelonephritis; yeast infection after 3 and more than 3 days of antibiotic therapy; medical visit due to yeast infection; changing the therapy (rather than extending the treatment) due to a lack of clinical response to TMP-SMZ or FQ; and clinical cure.
The probabilities of a clinical cure were assessed for: a FQ-resistant infection treated with a FQ (ciprofloxacin); a TMP-SMZ-resistant infection treated with TMP-SMZ; a FQ-susceptible infection treated with a FQ (ciprofloxacin); and a TMP-SMZ-susceptible infection treated with TMP-SMZ.
Study designs and other criteria for inclusion in the review
The estimates of clinical response were derived from prospective clinical trials or investigations.
Sources searched to identify primary studies
The authors searched MEDLINE from 1966 to June 2000. The manufacturers of three antibiotics were also contacted for additional response data.
Criteria used to ensure the validity of primary studies
No validity criteria were stated.
Methods used to judge relevance and validity, and for extracting data
The abstracts of articles were reviewed. Articles were selected for review if the abstracts suggested that they contained clinical cure rates for uncomplicated UTIs based on antimicrobial resistance.
Number of primary studies included
Twenty-two studies were included in the review.
Methods of combining primary studies
The mean value of the published estimates was taken as the base rate for the probabilities, with the highest and lowest probabilities forming the bounds for a sensitivity analysis. A range of at least -50% to +200% of the point estimate was used where there was one or no published source for the estimate. 
Measure of benefits used in the economic analysis
A cost-minimisation analysis was performed, thus there was no summary measure of health benefit.
Direct costs
The unit costs were reported. The total quantities were not reported, although they could be inferred from the text. The costs reported were relevant to a health service or a third-party payer. The costs of the following were included: the antibiotics, i.e. ciprofloxacin, generic TMP-SMZ and generic miconazole); hospitalisation for pyelonephritis; outpatient treatment for infection unresponsive to FQ treatment, or for pyelonephritis caused by FQ-resistant E. coli; the initial and follow-up physician visits; the urine culture; and the initial and follow-up urinalysis.
The antibiotic costs were taken from the Red Book of wholesale drug prices, 2 teaching hospitals, 5 retail pharmacies and 2 Internet pharmacies. The costs of hospitalisation and physician visits were taken from published literature and a survey of 2 teaching hospitals. The mean cost from each source was used in the base-case analysis. No distinction was made between the prices and the costs.
Discounting was irrelevant as the timeframe of the model was less than 1 year. The study reported the marginal costs.
The cost data were published between 1995 and 2000. No adjustment for inflation was reported. The cost results were not reported for any particular price year.
limiting the review to only prospective trials, the exclusion criteria for the studies were not stated. Also, it was not stated how the effectiveness data provided by the drug manufacturers were assessed for quality. The estimates of effectiveness were combined by calculating a mean value, and using the upper and lower estimates as bounds for the sensitivity analysis. By taking a raw mean value, which applies equal weight to all studies, factors such as the study sample size were not taken into account. However, the use of the upper and lower bounds in the sensitivity analysis reduced the possibility of bias.
Validity of estimate of measure of benefit
The analysis of benefits was based on the therapeutic equivalence of treatment alternatives. Therefore, the economic analysis only included the costs.
Validity of estimate of costs
All categories of cost relevant to a health care payer were included in the analysis. The unit costs were reported individually, but there was no summary table of the resource quantities. No distinction appears to have been made between the prices and the costs, even though some data were derived from retail sources while others came from wholesale or hospital sources.
A sensitivity analysis of the quantities was not undertaken, which may limit the interpretation of the study's findings.
A sensitivity analysis of the unit costs was performed, using the highest and lowest costs quoted from their sources as the extremities of the ranges. The costs were taken from sources published between 1995 and 2000, but there appears to have been no conversion to quote the prices in a consistent price year. This may affect the study's results. You should check whether the relative prices appear appropriate to your own setting.
